Literature DB >> 9322621

Angiogenesis in primary and metastatic epithelial ovarian carcinoma.

O Abulafia1, W E Triest, D M Sherer.   

Abstract

OBJECTIVE: Our goal was to evaluate angiogenesis in the ovaries and omental metastases as a prognostic indicator in patients with epithelial ovarian carcinoma. STUDY
DESIGN: Ovarian specimens of 42 consecutive patients with primary epithelial ovarian carcinoma (stages I to IV) and omental metastases of 19 of these patients with stage IIIB or stage IIIC disease were stained immunohistochemically for factor VIII-related antigen. Microvessel counts were tested for correlation with patient age, stage of disease, type of tumor, preoperative serum CA 125 level, tumor size, tumor resectability, patient survival, and omental microvessel counts. Statistical analysis included parametric (factorial analysis of variance) and nonparametric (Mann-Whitney and Kruskal-Wallis) group comparison tests, parametric (Pearson) and nonparametric (Spearman) correlation tests, and parametric (Cox proportional hazards) and nonparametric (Kaplan-Meier) survival analysis with p < 0.05 considered significant throughout.
RESULTS: Microvessel counts of omental metastases in patients with stage IIIB or stage IIIC ovarian carcinoma were significantly correlated with preoperative serum CA 125 level (p = 0.028) and patient survival (p = 0.019). Microvessel counts of the ovaries examined were not correlated with patient age, stage of disease, type of tumor, preoperative serum CA 125 level, tumor size, tumor resectability, patient survival, or microvessel count of the corresponding omental metastases.
CONCLUSION: Microvessel count of omental metastases is an independent prognostic indicator of survival in patients with advanced epithelial ovarian carcinoma and correlates with preoperative serum CA 125 level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322621     DOI: 10.1016/s0002-9378(97)70143-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients.

Authors:  Yunzhi Wang; Theresa Thai; Kathleen Moore; Kai Ding; Scott McMeekin; Hong Liu; Bin Zheng
Journal:  Oncol Lett       Date:  2016-05-31       Impact factor: 2.967

Review 2.  Tumor angiogenesis and molecular target therapy in ovarian carcinomas.

Authors:  Masatsugu Ueda; Yoshito Terai; Koji Kanda; Masanori Kanemura; Mikio Takehara; Hikari Futakuchi; Hiroyuki Yamaguchi; Masayuki Yasuda; Koji Nishiyama; Minoru Ueki
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

3.  Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study.

Authors:  B Davidson; I Goldberg; J Kopolovic; W H Gotlieb; V Givant-Horwitz; J M Nesland; A Berner; G Ben-Baruch; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

Review 5.  Vascular endothelial growth factor in ovarian cancer.

Authors:  D A Hazelton; T C Hamilton
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 6.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

7.  Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling.

Authors:  Boleslaw K Winiarski; Katarzyna I Wolanska; Srijana Rai; Tahanver Ahmed; Nigel Acheson; Nicholas J Gutowski; Jacqueline L Whatmore
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

Authors:  James Greenaway; Jack Henkin; Jack Lawler; Roger Moorehead; Jim Petrik
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

Review 9.  Current status of signal transduction modulators in the treatment of gynecologic malignancies.

Authors:  Shay Ashouri; Agustin A Garcia
Journal:  Curr Treat Options Oncol       Date:  2007-12

10.  Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Authors:  Anne M Schultheis; Georg Lurje; Katrin E Rhodes; Wu Zhang; Dongyun Yang; Agustin A Garcia; Robert Morgan; David Gandara; Sidney Scudder; Amit Oza; Hal Hirte; Gini Fleming; Lynda Roman; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.